MX2011008485A - Composiciones y metodos para terapia prolongada con aminopiridinas. - Google Patents

Composiciones y metodos para terapia prolongada con aminopiridinas.

Info

Publication number
MX2011008485A
MX2011008485A MX2011008485A MX2011008485A MX2011008485A MX 2011008485 A MX2011008485 A MX 2011008485A MX 2011008485 A MX2011008485 A MX 2011008485A MX 2011008485 A MX2011008485 A MX 2011008485A MX 2011008485 A MX2011008485 A MX 2011008485A
Authority
MX
Mexico
Prior art keywords
aminopyridine
patient
treatment
patients
average
Prior art date
Application number
MX2011008485A
Other languages
English (en)
Spanish (es)
Inventor
Andrew R Bligth
Ron Cohen
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011008485(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of MX2011008485A publication Critical patent/MX2011008485A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2011008485A 2009-02-11 2010-02-11 Composiciones y metodos para terapia prolongada con aminopiridinas. MX2011008485A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US15167909P 2009-02-11 2009-02-11
US25956309P 2009-11-09 2009-11-09
US28587209P 2009-12-11 2009-12-11
US28895309P 2009-12-22 2009-12-22
US29925910P 2010-01-28 2010-01-28
PCT/US2010/023970 WO2010093839A1 (en) 2009-02-11 2010-02-11 Compositions and methods for extended therapy with aminopyridines

Publications (1)

Publication Number Publication Date
MX2011008485A true MX2011008485A (es) 2011-11-04

Family

ID=42562065

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008485A MX2011008485A (es) 2009-02-11 2010-02-11 Composiciones y metodos para terapia prolongada con aminopiridinas.

Country Status (22)

Country Link
US (3) US20120029035A1 (OSRAM)
JP (1) JP2012517449A (OSRAM)
KR (3) KR20170034452A (OSRAM)
CN (2) CN102046174A (OSRAM)
AR (1) AR075413A1 (OSRAM)
AU (2) AU2010213663A1 (OSRAM)
BR (2) BRPI1000030A2 (OSRAM)
CA (1) CA2751581A1 (OSRAM)
CL (1) CL2011001927A1 (OSRAM)
CO (1) CO6440534A2 (OSRAM)
EA (1) EA022755B1 (OSRAM)
EC (1) ECSP11011311A (OSRAM)
IL (1) IL214500A0 (OSRAM)
MX (1) MX2011008485A (OSRAM)
NI (1) NI201100155A (OSRAM)
NZ (1) NZ595046A (OSRAM)
PE (1) PE20120791A1 (OSRAM)
SG (2) SG10201609184PA (OSRAM)
TN (1) TN2011000403A1 (OSRAM)
TW (2) TW201032809A (OSRAM)
UY (2) UY32444A (OSRAM)
WO (2) WO2010093838A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
US20150111930A1 (en) * 2013-10-23 2015-04-23 Afgin Pharma, Llc Topical regional neuro-affective therapy
TW201125562A (en) * 2009-09-04 2011-08-01 Acorda Therapeutics Inc Sustained release fampridine treatment in patients with multiple sclerosis
CN102442942A (zh) * 2010-10-08 2012-05-09 天津和美生物技术有限公司 4-氨基吡啶的多晶型物及其制备和应用
EP2995305B1 (en) * 2011-01-28 2020-03-04 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy
EP3381455A1 (en) * 2012-02-13 2018-10-03 Acorda Therapeutics, Inc. Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
WO2014028387A1 (en) * 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
EP3103096A4 (en) * 2014-02-04 2018-01-03 Optimata Ltd. Method and system for prediction of medical treatment effect
RU2580837C1 (ru) * 2015-05-05 2016-04-10 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе
US10172842B2 (en) 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
WO2022124946A1 (ru) * 2020-12-10 2022-06-16 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новые полиморфные формы 4-аминопиридина и их фармацевтическое применение
CN112914884B (zh) * 2021-01-19 2022-02-11 重庆火后草科技有限公司 通过稳态时长置信度测量睡眠状态下的体重值的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
US6288026B1 (en) * 1999-02-24 2001-09-11 Heinrich Exner Process and composition for treating diseases with an oil-in-water emulsion
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) * 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions

Also Published As

Publication number Publication date
TW201032809A (en) 2010-09-16
WO2010093838A1 (en) 2010-08-19
PE20120791A1 (es) 2012-07-08
TW201034665A (en) 2010-10-01
KR20120000560A (ko) 2012-01-02
EA022755B1 (ru) 2016-02-29
NZ595046A (en) 2013-10-25
US20150313886A1 (en) 2015-11-05
AU2016219650B2 (en) 2018-05-10
AU2016219650C1 (en) 2018-08-23
UY32444A (es) 2010-09-30
SG173641A1 (en) 2011-09-29
UY32445A (es) 2010-09-30
AR075413A1 (es) 2011-03-30
AU2010213663A1 (en) 2011-09-29
NI201100155A (es) 2012-02-16
KR20170034452A (ko) 2017-03-28
CN101896182A (zh) 2010-11-24
KR20180114250A (ko) 2018-10-17
CO6440534A2 (es) 2012-05-15
EA201171043A1 (ru) 2012-02-28
WO2010093839A1 (en) 2010-08-19
CL2011001927A1 (es) 2012-07-20
SG10201609184PA (en) 2016-12-29
BRPI1000030A2 (pt) 2018-02-14
ECSP11011311A (es) 2011-10-31
TN2011000403A1 (en) 2013-03-27
JP2012517449A (ja) 2012-08-02
US20120029035A1 (en) 2012-02-02
CA2751581A1 (en) 2010-08-19
AU2016219650A1 (en) 2016-09-15
IL214500A0 (en) 2011-09-27
US20170319562A1 (en) 2017-11-09
BRPI1000031A2 (pt) 2018-02-14
CN102046174A (zh) 2011-05-04

Similar Documents

Publication Publication Date Title
MX2011008485A (es) Composiciones y metodos para terapia prolongada con aminopiridinas.
JP2021119189A (ja) ジストニアを治療するためのプリドピジンの使用
AU2017315783A1 (en) Use of pridopidine for treating a subject with early stage huntington disease
US20220016095A1 (en) Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
AU2018364749C1 (en) Use of riluzole prodrugs to treat ataxias
US20130330277A1 (en) Methods of using sustained release aminopyridine compositions
US20250352533A1 (en) Pridopidine for treating huntington's disease
KR20120050512A (ko) 탈수초를 갖는 환자에서 ４-아미노피리딘을 사용한 지속적 치료
US20230270738A1 (en) Methods of treating agitation associated with alzheimer's disease
MX2014003997A (es) Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas.
US20240408086A1 (en) Use of luvadaxistat for the treatment of cognitive impairment
US20240342160A1 (en) Valbenazine for use in the treatment of dyskinesia due to cerebral palsy
US20240082215A1 (en) Use of mglur5 antagonists for treating gambling disorder
HK1157591A (en) Compositions and methods for extended therapy with aminopyridines
TW202438060A (zh) 用於治療夏柯-馬利-杜斯氏症的組成物及方法
EA041256B1 (ru) Применение придопидина для лечения ухудшения функциональной способности
CN117580576A (zh) Luvadaxistat用于治疗认知损害的用途
Singh et al. HIV Associated Arthritis
JP2018127497A (ja) アミノピリジンを使用した、ある種の卒中に関連した感覚運動障害を治療するための方法

Legal Events

Date Code Title Description
FC Refusal